ライフサイエンスコーパス: obstructive lung disease

1 triggers exacerbations of asthma and chronic obstructive lung disease.

2 sepsis, asthma, cystic fibrosis, and chronic obstructive lung disease.

3 the ventilatory mechanics of a patient with obstructive lung disease.

4 samples obtained from patients with chronic obstructive lung disease.

5 ibutable to heart failure and 12% to chronic obstructive lung disease.

6 ls with preexisting heart failure or chronic obstructive lung disease.

7 ent related to the severity of the patient's obstructive lung disease.

8 as yet to help patients with CF or any other obstructive lung disease.

9 n traits and identified a candidate gene for obstructive lung disease.

10 both in healthy volunteers and patients with obstructive lung disease.

11 t poor periodontal health is associated with obstructive lung disease.

12 uity between diagnosis of asthma and chronic obstructive lung disease.

13 igands may improve beta-agonist treatment of obstructive lung disease.

14 n lungs with chronic cigarette smoke-induced obstructive lung disease.

15 teria from the Global Initiative for Chronic Obstructive Lung Disease.

16 L-18 were also seen in patients with chronic obstructive lung disease.

17 hages from smokers and patients with chronic obstructive lung disease.

18 s impaired in cystic fibrosis (CF) and other obstructive lung diseases.

19 a novel approach to managing bronchospasm in obstructive lung diseases.

20 ulation mediates the pathogenesis of chronic obstructive lung diseases.

21 cessation of transport in persons with muco-obstructive lung diseases.

22 l/yr for GOLD (Global Initiative for Chronic Obstructive Lung Disease) 0-4 was as follows: 41.8 (47.7

23 ndromes, bronchiolitis, and cryptic cases of obstructive lung disease among United States citizens, s

24 rug that has long been used to treat chronic obstructive lung disease and acetaminophen toxicity and

25 ely increased in postviral mice with chronic obstructive lung disease and in humans with very severe

26 is the greatest risk factor for both chronic obstructive lung disease and interstitial lung disease.

27 dysplasia (BPD) is characterized by lifelong obstructive lung disease and profound, refractory bronch

28 is review, we first introduce representative obstructive lung diseases and examine limitations of cur

29 ory lung diseases, including asthma, chronic obstructive lung disease, and cystic fibrosis, which cau

30 respiratory diseases such as asthma, chronic obstructive lung disease, and cystic fibrosis.

31 pulmonary research and clinical practice in obstructive lung disease, and drug discovery platforms w

32 acute respiratory distress syndrome, chronic obstructive lung disease, and idiopathic pulmonary fibro

33 s in infants, exacerbations in patients with obstructive lung disease, and life-threatening pneumonia

34 l diagnoses of eosinophilic lung disease and obstructive lung disease, and marked eosinophilia in spu

35 s in infants, exacerbations in patients with obstructive lung disease, and pneumonia in immunocomprom

36 ease in particle deposition in patients with obstructive lung disease, and this can be an important f

37 Mortality rates of obstructive lung disease are starting to stabilize among

38 life (Short Form-36 [SF-36]), hypertension, obstructive lung disease, arthralgias, and peripheral ne

39 tube placement was seen in those with severe obstructive lung disease, as measured by percentage of p

40 f obstructive lung disease, the phenotype of obstructive lung disease associated with work-related or

41 the first line drugs in the treatment of the obstructive lung diseases asthma and chronic obstructive

42 and lung volumes in 29 patients with chronic obstructive lung disease before lung-volume-reduction su

43 ctive pulmonary disease (COPD) are prevalent obstructive lung diseases, both of which are characteriz

44 isease categories (restrictive lung disease, obstructive lung disease, bronchiectasis) were labelled

45 , compared to five of fifteen without severe obstructive lung disease, but this difference was not si

46 y duration, 5 yr) and the Canadian Cohort of Obstructive Lung Disease (CanCOLD) study (n = 1,551 subj

47 Chronic obstructive lung disease (COPD) and diffuse parenchymal

48 Asthma and chronic obstructive lung disease (COPD) are both inflammatory co

49 , normal smokers, smokers with early chronic obstructive lung disease (COPD), and smokers with establ

50 obstructive lung diseases asthma and chronic obstructive lung disease (COPD).

51 ic liver disease, viral hepatitis, overdose, obstructive lung disease, coronary artery disease, and p

52 met the GOLD (Global Initiative for Chronic Obstructive Lung Disease) criteria for COPD with quantit

53 position compared to supine in patients with obstructive lung disease, decreasing from 0.264+/-0.024

54 Patients with obstructive lung diseases display abnormal circadian rhy

55 mechanism, which is noxiously upregulated in obstructive lung diseases (e.g. chronic obstructive pulm

56 Patients with chronic obstructive lung disease experience an increased risk of

57 ds among people who died with a diagnosis of obstructive lung disease from 1979 through 1993, using d

58 s from four of the five subjects with severe obstructive lung disease gave a positive response to GRP

59 ingen Leiden Universities Corticosteroids in Obstructive Lung Disease (GLUCOLD) study.

60 den Universities study of Corticosteroids in Obstructive Lung Disease (GLUCOLD; n = 89).

61 art disease or stage 2 Global initiative for Obstructive Lung Disease (GOLD) COPD who had been clinic

62 defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criterion (FEV(1)/FVC <

63 (n = 116) with Global Initiative for Chronic Obstructive Lung Disease (GOLD) grade U (unclassified) o

64 for those with Global Initiative for Chronic Obstructive Lung Disease (GOLD) grades C-D (n = 558), 98

65 ince 2001, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) has published its strate

66 ne patients in Global Initiative for Chronic Obstructive Lung Disease (GOLD) II, 85 in GOLD III, and

67 terised by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) spirometric category (1-

68 ollows: having Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 3 or 4 disease at

69 Patients with Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage IV COPD had increa

70 Current Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy recommends the

71 The new Global Initiative for Obstructive Lung Disease (GOLD) stratification of chroni

72 nts with COPD (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage 4) and 28 samples

73 ery severe COPD (Global Health Initiative on Obstructive Lung Disease [GOLD] Stage IV) compared with

74 nts with GOLD [Global Initiative for Chronic Obstructive Lung Disease] grade 1B COPD, 11 age-matched

75 Based on Global Initiative for Chronic Obstructive Lung Disease guidelines, 461 patients (17.6%

76 Knowledge of genetic origins of obstructive lung diseases has made inhaled gene therapy

77 h pulmonary disease, particularly those with obstructive lung disease, have a high rate of panic symp

78 ta-agonists), in widespread clinical use for obstructive lung disease, have been associated with an i

79 chronic conditions, including frequent pain, obstructive lung disease, heart disease, diabetes, and p

80 d to second-hand smoke in the workplace, and obstructive lung disease history.

81 onfidence interval [CI], 1.12-2.10), chronic obstructive lung disease (HR, 1.56; CI, 1.15-2.10), fema

82 cedents, 2,554,959 (8.2%) had a diagnosis of obstructive lung disease (ICD-9 490 to 493.9, 496) liste

83 y severe COPD (Global Initiative for Chronic Obstructive Lung Disease III/IV) compared with both smok

84 mild restrictive pattern in DL-S and severe obstructive lung disease in DL-OBS.

85 e delivery of aerosolised bronchodilators in obstructive lung disease in general.

86 high prevalence of respiratory symptoms and obstructive lung disease in HIV-infected subjects, the p

87 tis (DPB), an important cause of progressive obstructive lung disease in the Far East, represents a d

88 prevention of Pneumocystis colonization and obstructive lung disease in the SHIV model.

89 of the increased risk and manifestations of obstructive lung diseases in HIV-infected patients and s

90 major pathophysiological hallmarks of severe obstructive lung diseases including chronic obstructive

91 Chronic obstructive lung disease is characterized by persistent

92 Obstructive lung disease is the most common form of resp

93 We conclude that mortality related to obstructive lung disease is under-estimated in studies t

94 Data are from the Inhaled Steroids in Obstructive Lung Disease (ISOLDE) trial.

95 54,959 decedents, only 1,106,614 (43.3%) had obstructive lung disease listed as the underlying cause

96 The findings support that chronic obstructive lung diseases may have at least part of thei

97 tterns in eight patients with severe chronic obstructive lung disease (median FEV1 = 0.79 L, range 0.

98 adenovirus bronchiolitis or pneumonia, fixed obstructive lung disease on pulmonary function testing,

99 did not have heart disease, stroke, chronic obstructive lung disease, or cancer at the time they ans

100 flammatory disease, transplantation, chronic obstructive lung disease, other cancers, and hypopituita

101 lines from the Global Initiative for Chronic Obstructive Lung Disease reorganised treatment objective

102 ive for Asthma/Global Initiative for Chronic Obstructive Lung Disease report, to provide health profe

103 by using the composite Global Initiative for Obstructive Lung Disease scale (P < .0001).

104 Many patients with chronic obstructive lung disease show increased airways responsi

105 ants (11%) met Global Initiative for Chronic Obstructive Lung Disease spirometric criteria for lung-f

106 test effect in Global Initiative for Chronic Obstructive Lung Disease stage 1, where each exacerbatio

107 re observed in Global Initiative for Chronic Obstructive Lung Disease stage 2 and 3 subjects.

108 subjects with Global Initiative for Chronic Obstructive Lung Disease stage I COPD and 20 healthy sub

109 nts with COPD (Global Initiative for Chronic Obstructive Lung Disease stage I to II) before and after

110 patients with Global Initiative for Chronic Obstructive Lung Disease stage I-IV COPD, and smoking an

111 nts with COPD (Global Initiative for Chronic Obstructive Lung Disease stage II-IV) underwent hyperpol

112 gnosis of COPD Global Initiative for Chronic Obstructive Lung Disease stage II-IV.

113 age and milder Global Initiative for Chronic Obstructive Lung Disease stage were associated with bett

114 ema, increased Global Initiative for Chronic Obstructive Lung Disease stage, and COPD disease status.

115 cise index, or Global Initiative for Chronic Obstructive Lung Disease stage.

116 nt wheeze, and Global Initiative for Chronic Obstructive Lung Disease stages 2 and higher chronic obs

117 d >/=40 years, Global Initiative for Chronic Obstructive Lung Disease stages III-IV, and one or more

118 nts and milder Global Initiative for Chronic Obstructive Lung Disease stages.

119 ] years, GOLD (Global Initiative for Chronic Obstructive Lung Disease) stages I-IV: 9.4, 42.5, 37.5,

120 s based on the Global Initiative for Chronic Obstructive Lung Disease staging criteria were adjusted

121 conference symposium titled "Depression and Obstructive Lung Disease: State of the Science and Futur

122 Endpoints), and GenKOLS (Genetics of Chronic Obstructive Lung Disease) studies were analyzed.

123 articipating in the CanCOLD (Canadian Cohort Obstructive Lung Disease) study, with at least 12 months

124 Applications in patients with obstructive lung diseases, such as asthma and chronic ob

125 eful technique for image-guided treatment of obstructive lung diseases, such as bronchial thermoplast

126 iolitis obliterans is a rare form of chronic obstructive lung disease that follows a severe insult to

127 ) is a prominent feature of asthma and other obstructive lung diseases that is minimally affected by

128 hypertension, diabetes mellitus, or chronic obstructive lung disease), the age-adjusted hazard ratio

129 es contribute to a significant proportion of obstructive lung disease, the phenotype of obstructive l

130 for efficacious bronchodilators for treating obstructive lung diseases, this pathway can be exploited

131 ld smoking may predispose neonates with muco-obstructive lung disease to bacterial exacerbations.

132 previously established mouse model of severe obstructive lung diseases, to produce lower-mortality bu

133 significant decrease in Rrs in patients with obstructive lung disease was also observed.

134 tory failure (end-tidal CO2 of 75 mm Hg) and obstructive lung disease were simulated in a double-cham

135 outh demonstrated decreased reversibility of obstructive lung disease, which is atypical of asthma.

136 he longitudinal Tucson Epidemiology Study of Obstructive Lung Disease who had at least one DL(CO) mea

137 disease (COPD) are highly prevalent chronic obstructive lung diseases with an associated high burden